Discovery of an LSD1 PROTAC degrader
Proceedings of the National Academy of Sciences · 20.05.2025 · 122 (20)
DOI: 10.1073/pnas.2425812122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.05.2025. Verfasst von Amir Hosseini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom. Hauptthemen laut MEDLINE: Histone Demethylases, Proteolysis, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
Aberrant expression of lysine-specific demethylase 1 (LSD1) has been implicated in various cancers, including acute myeloid leukemia (AML). Recent studies have revealed both catalytic and noncatalytic oncogenic functions of LSD1, which cannot be effectively addressed by traditional small-molecule inhibitors. Therefore, to remove LSD1 and mitigate its oncogenic activity, we utilized the proteolysis-targeting chimera (PROTAC) approach and developed an LSD1 PROTAC degrader MS9117, which recruits the E3 ligase cereblon (CRBN). MS9117 induces LSD1 degradation in a concentration-, time-, CRBN-, and proteasome-dependent manner. Importantly, MS9117 effectively degrades LSD1 and demonstrates superior antiproliferative effects in AML cells, compared to the existing pharmacological LSD1 inhibitors. Furthermore, MS9117 also sensitized nonacute promyelocytic leukemia AML cells to all-trans retinoic acid treatment. Moreover, we developed two negative controls of MS9117, MS9117N1 and MS9117N2, which do not degrade LSD1 or inhibit leukemia cell growth, further confirming the mechanism of action of MS9117. Overall, MS9117 serves as a valuable chemical tool and a potential therapeutic to target both the catalytic and scaffolding functions of LSD1. With several LSD1 inhibitors already in clinical development, the LSD1 degraders such as MS9117 offer an additional option for future clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom.
- Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
- Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
ORCID-Profile: Jerrel Catlett, Yang Shi, Jian Jin
Förderung
- NIH HHS
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Hosseini, A., Qiu, X., Xiong, Y., Chiang, K. H. N., Catlett, J., Kaltheuner, I., Deng, Z., Ghosh, S., Shi, Y., & Jin, J. (2025). Discovery of an LSD1 PROTAC degrader. Proceedings of the National Academy of Sciences, 122(20). https://doi.org/10.1073/pnas.2425812122
Vancouver
Hosseini A, Qiu X, Xiong Y, Chiang KHN, Catlett J, Kaltheuner I, et al. Discovery of an LSD1 PROTAC degrader. Proceedings of the National Academy of Sciences. 2025;122(20). doi:10.1073/pnas.2425812122
BibTeX
@article{Hosseini2025,
author = {Hosseini, Amir and Qiu, Xing and Xiong, Yan and Chiang, Ki Him Nicholas and Catlett, Jerrel and Kaltheuner, Ines and Deng, Zhijie and Ghosh, Sudipta and Shi, Yang and Jin, Jian},
title = {Discovery of an LSD1 PROTAC degrader},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {20},
doi = {10.1073/pnas.2425812122}
}
EUVIMED